Abstract
Immune checkpoint blockade is effective in treating many human cancers. In this issue of Cell, Luoma etal. show that tissue-resident memory Tcells in head and neck cancers rapidly respond to immune checkpoint blockade, and they identify specific CD8+ Tcells in pretreatment blood that predict pathologic tumor regression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
